Rosacea - Pipeline Review, H1 2018

  • ID: 4529318
  • Report
  • 61 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Almirall SA
  • Amorepacific Corp
  • BioPharmX Inc
  • Cutanea Life Sciences Inc
  • ELORAC Inc
  • Hovione FarmaCiencia SA
  • MORE
Rosacea - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Rosacea - Pipeline Review, H1 2018, provides an overview of the Rosacea (Dermatology) pipeline landscape.

Rosacea is a chronic and potentially life-disruptive disorder primarily of the facial skin, often characterized by flare-ups and remissions. Symptoms include frequent redness of the face, or flushing, small, red lines under the skin, a swollen nose and thick skin, usually on the forehead, chin, and cheeks. The predisposing factors include age and family history of rosacea. Treatment includes antibiotics and acne drugs.

Report Highlights:

This latest pipeline guide Rosacea - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Rosacea (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rosacea (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Rosacea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 9, 5, 1 and 1 respectively.

Rosacea (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Rosacea (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Rosacea (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Rosacea (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Rosacea (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Rosacea (Dermatology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Rosacea (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Rosacea (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Almirall SA
  • Amorepacific Corp
  • BioPharmX Inc
  • Cutanea Life Sciences Inc
  • ELORAC Inc
  • Hovione FarmaCiencia SA
  • MORE
Introduction

Report Coverage

Rosacea - Overview

Rosacea - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Rosacea - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Rosacea - Companies Involved in Therapeutics Development

Almirall SA

Amorepacific Corp

BioPharmX Inc

Cutanea Life Sciences Inc

ELORAC Inc

Foamix Pharmaceuticals Ltd

Hovione FarmaCiencia SA

Promius Pharma LLC

Sol-Gel Technologies Ltd

Rosacea - Drug Profiles

AC-701 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ACUD-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADP-13612 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

benzoyl peroxide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologics for Dermatology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BPX-04 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

carbamide peroxide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DMT-210 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DMT-220 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EP-0003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FMX-103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

itraconazole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

minocycline - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

minocycline hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MSB-03 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omiganan pentahydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PAC-14028 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

phenylbutyrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Rosacea - Dormant Projects

Rosacea - Discontinued Products

Rosacea - Product Development Milestones

Featured News & Press Releases

Feb 15, 2018: Sol-Gel presents Phase 2 Data on VERED at the 2018 American Academy of Dermatology Annual Meeting

Dec 13, 2017: Hovione Announces Enrollment of First Patient in MARS, a Phase 2 Clinical Trial for the Treatment of Moderate to Severe Inflammatory Rosacea with its Proprietary Minocycline Topical Gel

Jun 12, 2017: Foamix Announces Dosing of First Patient in Phase 3 Rosacea Clinical Trials for FMX103 Minocycline Foam 1.5%

Jan 18, 2017: Dermata Therapeutics Announces Initiation of Treatment in a Phase 2 Acne Rosacea Clinical Study

Sep 28, 2016: Dermata Therapeutics, LLC Announces Positive Top-line Results from their Phase 1 Pharmacokinetic Study of DMT210 in Acne Rosacea Patients

Sep 12, 2016: Foamix Announces Positive Topline Results from Phase 2 Trial Evaluating FMX-103 Topical Minocycline Foam for Moderate-to-Severe Papulopustular Rosacea

Sep 09, 2016: Foamix to Announce Topline Results in Phase 2 Clinical Trial of FMX-103 Minocycline Topical Foam for Moderate-to-Severe Papulopustular Rosacea

May 19, 2016: Galderma Laboratories Announces Availability of New Mirvaso (brimonidine) Topical Gel, 0.33% Pump Dispenser for the Treatment of the Persistent Facial Redness of Rosacea

May 16, 2016: Dermata Therapeutics Announces Initiation of Phase 1 Pharmacokinetic Study

May 03, 2016: Foamix Announces Completion of Enrollment in Phase 2 Clinical Trial of Minocycline Foam (FMX103) for Treatment of Papulopustular Rosacea

Oct 20, 2015: Foamix Announces Enrollment of First Patient in Phase 2 Clinical Trial of FMX103 in Papulopustular Rosacea

Apr 17, 2014: Treatment for Facial Redness Associated With Rosacea Now Available in the UK

Feb 26, 2014: Mirvaso the first and only treatment targeting the facial redness of rosacea approved by the European commission

Jan 29, 2014: Galderma Announces the Publication of Positive Results of the Long-Term Study of Mirvaso Gel for Treatment of Persistent Erythema of Rosacea

Dec 20, 2013: Galderma Receives CHMP Positive Opinion For Mirvaso

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Table 1: Number of Products under Development for Rosacea, H1 2018

Table 2: Number of Products under Development by Companies, H1 2018

Table 3: Products under Development by Companies, H1 2018

Table 4: Number of Products by Stage and Target, H1 2018

Table 5: Number of Products by Stage and Mechanism of Action, H1 2018

Table 6: Number of Products by Stage and Route of Administration, H1 2018

Table 7: Number of Products by Stage and Molecule Type, H1 2018

Table 8: Rosacea - Pipeline by Almirall SA, H1 2018

Table 9: Rosacea - Pipeline by Amorepacific Corp, H1 2018

Table 10: Rosacea - Pipeline by BioPharmX Inc, H1 2018

Table 11: Rosacea - Pipeline by Cutanea Life Sciences Inc, H1 2018

Table 12: Rosacea - Pipeline by ELORAC Inc, H1 2018

Table 13: Rosacea - Pipeline by Foamix Pharmaceuticals Ltd, H1 2018

Table 14: Rosacea - Pipeline by Hovione FarmaCiencia SA, H1 2018

Table 15: Rosacea - Pipeline by Promius Pharma LLC, H1 2018

Table 16: Rosacea - Pipeline by Sol-Gel Technologies Ltd, H1 2018

Table 17: Rosacea - Dormant Projects, H1 2018

Table 18: Rosacea - Dormant Projects, H1 2018 (Contd..1), H1 2018

Table 19: Rosacea - Discontinued Products, H1 2018

List of Figures

Figure 1: Number of Products under Development for Rosacea, H1 2018

Figure 2: Number of Products under Development by Companies, H1 2018

Figure 3: Number of Products by Top 10 Targets, H1 2018

Figure 4: Number of Products by Stage and Top 10 Targets, H1 2018

Figure 5: Number of Products by Top 10 Mechanism of Actions, H1 2018

Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Figure 7: Number of Products by Routes of Administration, H1 2018

Figure 8: Number of Products by Stage and Routes of Administration, H1 2018

Figure 9: Number of Products by Molecule Types, H1 2018

Figure 10: Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Almirall SA
  • Amorepacific Corp
  • BioPharmX Inc
  • Cutanea Life Sciences Inc
  • ELORAC Inc
  • Foamix Pharmaceuticals Ltd
  • Hovione FarmaCiencia SA
  • Promius Pharma LLC
  • Sol-Gel Technologies Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll